NCT06781125View on ClinicalTrials.gov

One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

March 30, 2028

Study Completion Date

June 30, 2028

Conditions
Malignant Solid Tumors
Interventions
DRUG

JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion

"JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability .~Anti-PD-1 antibody:Dosage and administration according to the instructions."

Sponsors
All Listed Sponsors
lead

Immorna Biotherapeutics, Inc.

INDUSTRY